Korro Bio is no longer the company that took a lipid-nanoparticle RNA editor into humans; it is a smaller, GalNAc-only platform trying to prove that the first clinical miss was a delivery failure rather than a verdict on oligonucleotide-promoted RNA editing itself.
The load-bearing development is the November termination of the prior AATD editor after the first-in-human REWRITE study failed to reach the projected protein levels in alpha-1 antitrypsin deficiency, the genetic liver-and-lung disease that had been the public face of the platform. That miss collapsed the lipid-nanoparticle thesis, forced a second-half workforce cut of about a third, and coincided with a twelve-month pause of the Novo Nordisk cardiometabolic collaboration. The mechanism is straightforward: once the first human experiment under-delivered protein, both the internal burn and the partner's target rationale became untenable, and the residual equity case shifted onto KRRO-121, a GalNAc-conjugated editor designed to create a more stable glutamine synthetase variant for hyperammonemia, plus a newly nominated GalNAc AATD candidate, KRRO-111. Shareholders now own a rebuilt pipeline rather than a continuation of the program that already failed.
The tension is that the rebuild is scientifically coherent and still clinically unproven. Preclinical GalNAc data on KRRO-111 show high editing of the SERPINA1 transcript and a sharp drop in pathogenic Z-protein in mouse models, and the European Medicines Agency granted orphan designation to KRRO-121 for urea cycle disorders. None of that repairs the fact that the only human test of the OPERA chemistry, the company's oligonucleotide-promoted RNA-editing method, already missed its protein target. Cash of $138 million at mid-year and a stated runway into late 2028 buy time. They do not buy evidence.
The next resolution is whether the hyperammonemia editor clears a regulatory filing and enters first-in-human testing later this year. That filing is the first chance to test the delivery-pivot story in people rather than in mice.